Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Key Resources and Organizations for Precision Medicine Guidelines

MedGenome Strengthens Leadership Team to Drive North American Expansion in Precision Medicine

NCCN Expands Clinical Practice Guidelines for High-Risk Genetic Cancer Assessment

Home
/
update
/
details

Roche to Present Over 40 Abstracts on Blood Disorders at 66th ASH Annual Meeting, Showcasing Advances in Lymphoma Treatments

NextEdge Admin

07 Nov 2024

2 min 21 sec

Roche announced its plans to present over 40 abstracts on nine blood disorders at the 66th American Society of Hematology (ASH) Annual Meeting from December 7-10, 2024, in San Diego, USA. These data reflect Roche’s commitment to advancing lymphoma treatments, featuring long-term results from approved therapies Polivy® (polatuzumab vedotin), Lunsumio® (mosunetuzumab), and Columvi® (glofitamab), along with findings from investigational combination studies.

Key presentations include five-year data from the phase III POLARIX study (abstract #469), which demonstrates Polivy’s potential to improve overall survival when combined with MabThera®/Rituxan® (rituximab) and chemotherapy (R-CHP) for first-line diffuse large B-cell lymphoma (DLBCL)—a field with limited progress in recent decades. Roche will also present four-year follow-up data from the Lunsumio (GO29781, abstract #4407) and Columvi (NP30179, abstract #865) studies, showing durable remissions and immune recovery in third-line or later (3L+) follicular lymphoma (FL) and DLBCL patients, supporting the use of fixed-duration bispecific antibody treatments.

In addition, data from a subcutaneous formulation of Lunsumio (abstract #1645) indicate high response rates and minimal cytokine release syndrome for 3L+ FL, with the potential to improve patient experience through shorter administration times. Results from the STARGLO study (abstract #5132) further highlight quality-of-life benefits with Columvi for second-line DLBCL. Finally, new findings from combination studies of Polivy with Lunsumio and Columvi (abstracts #988 and #989) underscore the promise of these regimens for relapsed or refractory DLBCL, supporting further phase III trials for earlier treatment lines.